Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Asfar Sohail Azmi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1178-9505; OpenAlex author ID A5026049304; NIH RePORTER profile ID 9609623. Sources: OpenAlex.

Their work

Papers
55 (first author 6, last author 21)
Trials
0
Grants
2
Labs led
1
Collaborators
67
Papers, trials and grants by year

2011: 9 papers · 2012: 3 papers · 2013: 2 papers · 2014: 6 papers · 2015: none · 2016: 1 paper, 1 grant · 2017: 3 papers · 2018: 3 papers · 2019: 4 papers · 2020: 2 papers · 2021: 4 papers · 2022: 5 papers · 2023: 3 papers · 2024: 2 papers, 1 grant · 2025: 4 papers · 2026: 4 papers

Papers 50 of 55

  1. XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2026.218804↗
  2. Daraxonrasib in pancreatic cancer: When progress disrupts practice. Co-author DOI 10.1016/j.drudis.2026.104761↗
  3. Ranking targeted therapies in advanced pancreatic adenocarcinoma: insights from a network meta-analysis. Last author DOI 10.21037/jgo-2026-0209↗
  4. ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.02.11.705411↗
  5. Pharmacological advances in cannabinoid-based therapies for pancreatic cancer: preclinical efficacy of CCL-106 and its epimers. Co-author DOI 10.1016/j.esmogo.2025.100211↗
  6. Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Last author DOI 10.1101/2025.11.21.689857↗
  7. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-025-02288-9↗
  8. PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer Last author DOI 10.64898/2025.12.06.692635↗
  9. Deciphering cellular plasticity in pancreatic cancer for effective treatments. Last author DOI 10.1007/s10555-023-10164-5↗
  10. RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. Last author DOI 10.1016/j.canlet.2024.217275↗
  11. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. Last author DOI 10.1002/ctm2.1513↗
  12. Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. Last author DOI 10.1016/j.adro.2022.101122↗
  13. Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis Last author DOI 10.1101/2023.12.18.572102↗
  14. Connecting the Human Microbiome and Pancreatic Cancer. Last author DOI 10.1007/s10555-022-10022-w↗
  15. Correction to: Connecting the human microbiome and pancreatic cancer. Last author DOI 10.1007/s10555-022-10037-3↗
  16. Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer … Last author DOI 10.1101/2022.03.08.481108↗
  17. Role of noncoding RNAs in pancreatic ductal adenocarcinoma associated cachexia. Co-author DOI 10.1152/ajpcell.00424.2022↗
  18. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? Last author DOI 10.3389/fonc.2022.1013902↗
  19. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Last author DOI 10.1007/s10555-021-09990-2↗
  20. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Last author DOI 10.1007/s10555-021-09993-z↗
  21. Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. Last author DOI 10.3390/cancers13112777↗
  22. Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. Co-author DOI 10.3390/cancers13164161↗
  23. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-1728↗
  24. Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. Last author DOI 10.3390/cancers12030750↗
  25. miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.ajpath.2018.10.005↗
  26. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. First author DOI 10.1080/14656566.2018.1561869↗
  27. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarc… Last author DOI 10.1080/21541248.2017.1329694↗
  28. DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcin… Co-author DOI 10.3390/cancers11081101↗
  29. Retraction notice to "Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells". Co-author DOI 10.1016/j.canlet.2018.03.020↗
  30. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Co-author DOI 10.1080/14737140.2018.1417844↗
  31. Nuclear Export Inhibition for Pancreatic Cancer Therapy. First author DOI 10.3390/cancers10050138↗
  32. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1535-7163.mct-16-0205↗
  33. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Co-author DOI 10.18632/oncotarget.17869↗
  34. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Co-author DOI 10.18632/oncotarget.19285↗
  35. The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm5060059↗
  36. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. First author DOI 10.1074/jbc.m113.532887↗
  37. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Co-author DOI 10.1089/scd.2013.0551↗
  38. A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Co-author DOI 10.1158/1535-7163.mct-12-0767↗
  39. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. First author DOI 10.18632/oncotarget.1813↗
  40. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Last author DOI 10.2147/ott.s40705↗
  41. Systems biology approaches to pancreatic cancer detection, prevention and treatment. Last author DOI 10.2174/138161282001140113124643↗
  42. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. Co-author DOI 10.1002/jcp.24162↗
  43. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Co-author DOI 10.1053/j.gastro.2012.10.036↗
  44. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Co-author DOI 10.1158/1940-6207.capr-11-0299↗
  45. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. Co-author DOI 10.1371/journal.pone.0050165↗
  46. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. Co-author DOI 10.1371/journal.pone.0052095↗
  47. Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. Co-author DOI 10.1002/ijc.25658↗
  48. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. Co-author DOI 10.1002/jcb.23150↗
  49. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2011.03.012↗
  50. Pancreatic cancer: understanding and overcoming chemoresistance. Co-author DOI 10.1038/nrgastro.2010.188↗

Grants 2

  1. Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer R37CA215427↗
  2. Targeting PAK4 for Overcoming Drug Resistance in Pancreatic Cancer R21CA188818↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Philip A. Philip · 24 shared papers, 2011–2026 · strength 3.84
  2. Amro Aboukameel · 23 shared papers, 2012–2026 · strength 2.57
  3. Ramzi M. Mohammad · 22 shared papers, 1 shared grant, 2011–2026 · strength 2.50
  4. Husain Yar Khan · 14 shared papers, 2020–2026 · strength 2.26
  5. Md. Hafiz Uddin · 13 shared papers, 2021–2026 · strength 2.15
  6. Sahar F. Bannoura · 12 shared papers, 2021–2026 · strength 1.99
  7. Bassel F. El‐Rayes · 10 shared papers, 2021–2026 · strength 1.78
  8. Yiwei Li · 19 shared papers, 2011–2023 · strength 1.50
  9. Muhammad Wasif Saif · 5 shared papers, 2024–2026 · strength 1.22
  10. Irfana Muqbil · 9 shared papers, 2016–2024 · strength 1.09
  11. Bin Bao · 15 shared papers, 2011–2026 · strength 0.97
  12. Boris Pasche · 5 shared papers, 2023–2026 · strength 0.88
  13. Eliza Wright Beal · 4 shared papers, 2023–2026 · strength 0.70
  14. Anthony Frank Shields · 4 shared papers, 2022–2026 · strength 0.64
  15. Steve H. Kim · 5 shared papers, 2020–2025 · strength 0.63
  16. Mandana Kamgar · 5 shared papers, 2018–2023 · strength 0.59
  17. Fazlul H. Sarkar · 16 shared papers, 2011–2018 · strength 0.57
  18. Rachel E. Sexton · 4 shared papers, 2020–2022 · strength 0.50
  19. Kay‐Uwe Wagner · 3 shared papers, 2021–2024 · strength 0.48
  20. Anteneh A. Tesfaye · 4 shared papers, 2018–2020 · strength 0.47
  21. Sanjeev Banerjee · 12 shared papers, 2011–2018 · strength 0.41
  22. Yulia Y. Maxuitenko · 2 shared papers, 2025–2026 · strength 0.41
  23. Donald J Buchsbaum · 2 shared papers, 2025–2026 · strength 0.41
  24. Adam B. Keeton · 2 shared papers, 2025–2026 · strength 0.41
  25. Sujith Sarvesh · 2 shared papers, 2025–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.